Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INBS 
Intelligent Bio Solutions Inc. (INBS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: INBS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -81.34% | Avg. Invested days 20 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.88M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 4.59 | 52 Weeks Range 1.10 - 2.75 | Updated Date 09/17/2025 |
52 Weeks Range 1.10 - 2.75 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -341.46% |
Management Effectiveness
Return on Assets (TTM) -59.15% | Return on Equity (TTM) -192.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 16142483 | Price to Sales(TTM) 5.53 |
Enterprise Value 16142483 | Price to Sales(TTM) 5.53 | ||
Enterprise Value to Revenue 5.29 | Enterprise Value to EBITDA -0.91 | Shares Outstanding 8979040 | Shares Floating 8261179 |
Shares Outstanding 8979040 | Shares Floating 8261179 | ||
Percent Insiders 1.05 | Percent Institutions 7.99 |
Upturn AI SWOT
Intelligent Bio Solutions Inc.
Company Overview
History and Background
Intelligent Bio Solutions Inc. focuses on developing and commercializing rapid, point-of-care diagnostics and drug screening solutions. It aims to address unmet needs in various markets using its technology.
Core Business Areas
- Point-of-Care Diagnostics: Development and commercialization of rapid diagnostic tests for various diseases and health conditions.
- Drug Screening: Providing solutions for rapid drug screening and substance abuse detection.
Leadership and Structure
Information about the specific leadership team and detailed organizational structure is not readily available without deeper research.
Top Products and Market Share
Key Offerings
- Intelligent Fingerprinting Drug Screening System: A fingerprint-based drug screening system for detecting drugs of abuse. The market share is evolving as they expand their commercial footprint. Competitors include traditional urine and saliva-based drug testing companies like Quest Diagnostics and Laboratory Corporation of America (LabCorp).
Market Dynamics
Industry Overview
The point-of-care diagnostics and drug screening industries are experiencing growth due to increased demand for rapid and convenient testing solutions.
Positioning
Intelligent Bio Solutions Inc. aims to differentiate itself with its fingerprint-based technology, offering a non-invasive and potentially more convenient alternative to traditional methods.
Total Addressable Market (TAM)
The combined market for point-of-care diagnostics and drug screening is estimated to be in the billions of dollars. Intelligent Bio Solutions Inc. is positioned to capture a share of this market with its unique technology.
Upturn SWOT Analysis
Strengths
- Innovative fingerprint-based technology
- Non-invasive testing method
- Potential for rapid results
- Point of care advantage
Weaknesses
- Limited commercial track record
- Relatively small market share
- Dependence on successful product launches
- Limited brand recognition
Opportunities
- Expanding into new geographic markets
- Developing new applications for the technology
- Partnering with healthcare providers and employers
- Increasing demand for rapid drug screening
Threats
- Competition from established players
- Regulatory hurdles
- Technological advancements by competitors
- Market adoption challenges
Competitors and Market Share
Key Competitors
- QDEL
- LH
- DGX
Competitive Landscape
Intelligent Bio Solutions Inc. faces stiff competition from established players with greater resources and market presence. Its fingerprint technology offers a unique selling proposition, but it needs to overcome adoption challenges.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth data available due to its relatively early stage.
Future Projections: Future growth depends on the successful commercialization and adoption of its products.
Recent Initiatives: Focusing on expanding its sales and marketing efforts and securing regulatory approvals.
Summary
Intelligent Bio Solutions Inc. is an early-stage company with a novel fingerprint-based drug screening technology. While its innovative approach holds promise, it faces significant challenges in competing with established players and achieving widespread market adoption. Success hinges on effective commercialization, regulatory approvals, and continued product development. The company's small market share and limited financial track record present risks for investors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Press releases
- Industry reports
- Market analysis
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intelligent Bio Solutions Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-12-23 | President & CEO Mr. Harry Simeonidis | ||
Sector Healthcare | Industry Medical Devices | Full time employees 53 | Website https://ibs.inc |
Full time employees 53 | Website https://ibs.inc | ||
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.